9M33 image
Deposition Date 2025-02-28
Release Date 2025-09-17
Last Version Date 2025-10-22
Entry Detail
PDB ID:
9M33
Title:
DjCas13d-crRNA-target RNA1 ternary complex
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.27 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:DjCas13d
Chain IDs:A
Chain Length:877
Number of Molecules:1
Biological Source:Ruminococcus sp. UBA7013
Polymer Type:polyribonucleotide
Molecule:RNA (51-MER)
Chain IDs:B
Chain Length:51
Number of Molecules:1
Biological Source:Ruminococcus sp. UBA7013
Polymer Type:polyribonucleotide
Molecule:RNA (30-MER)
Chain IDs:C
Chain Length:30
Number of Molecules:1
Biological Source:Ruminococcus sp. UBA7013
Ligand Molecules
Primary Citation
Mechanistic insights into Cas13d enzymes from cryo-EM structures of CasRx and DjCas13d.
Nucleic Acids Res. 53 ? ? (2025)
PMID: 41036620 DOI: 10.1093/nar/gkaf986

Abstact

CasRx and its engineered variants have emerged as powerful RNA-targeting tools, exhibiting high specificity, robust efficiency, and minimal trans-cleavage activity. Recently, DjCas13d was identified as a promising alternative, offering even lower trans-cleavage activity while retaining comparable cis-cleavage efficiency. Despite their broad utility in biotechnology and therapeutic development, the molecular mechanisms governing substrate recognition and activation in these functionally relevant Cas13d enzymes remain incompletely understood. Here, we present comparative structural and biochemical analyses of CasRx and DjCas13d. Using cryogenic electron microscopy, we determined structures of both enzymes in binary (protein-crRNA) and ternary (protein-crRNA-target RNA) states, and additionally solved the apo structure of DjCas13d. Biochemical assays revealed that both enzymes exhibit similar cis-cleavage activity, whereas DjCas13d shows substantially reduced trans-cleavage activity relative to CasRx. Structural comparisons uncovered key conformational changes linked to target RNA engagement and catalytic activation, providing mechanistic insight into their distinct cleavage behaviors. Furthermore, structure-guided mutagenesis yielded several CasRx variants that achieve a favorable balance between reduced trans-cleavage activity and preserved cis-cleavage efficiency, representing valuable starting points for further optimization. Together, these findings advance our mechanistic understanding of Cas13 enzymes and provide a structural framework for the rational design of RNA-targeting technologies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures